Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications
<p>Due to the strong association between diabetes and cancer incidents, several anti-diabetic drugs, including metformin, have been examined for their anticancer activity. Metformin is a biguanide antihyperglycemic agent used as a first-line drug for type II diabetes mellitus. It exhibits anti...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513530417381376 |
|---|---|
| author | Sara S Bashraheel (17807612) |
| author2 | Hadeel Kheraldine (14231609) Sarah Khalaf (16555642) Ala-Eddin Al Moustafa (5472368) |
| author2_role | author author author |
| author_facet | Sara S Bashraheel (17807612) Hadeel Kheraldine (14231609) Sarah Khalaf (16555642) Ala-Eddin Al Moustafa (5472368) |
| author_role | author |
| dc.creator.none.fl_str_mv | Sara S Bashraheel (17807612) Hadeel Kheraldine (14231609) Sarah Khalaf (16555642) Ala-Eddin Al Moustafa (5472368) |
| dc.date.none.fl_str_mv | 2023-06-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.biopha.2023.114676 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Metformin_and_HER2-positive_breast_cancer_Mechanisms_and_therapeutic_implications/25018259 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Metformin Diabetes HER2 Breast cancer HER2/IGF-1R interaction |
| dc.title.none.fl_str_mv | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>Due to the strong association between diabetes and cancer incidents, several anti-diabetic drugs, including metformin, have been examined for their anticancer activity. Metformin is a biguanide antihyperglycemic agent used as a first-line drug for type II diabetes mellitus. It exhibits anticancer activity by impacting different molecular pathways, such as AMP-inducible protein kinase (AMPK)-dependent and AMPK-independent pathways. Additionally, Metformin indirectly inhibits IGF-1R signaling, which is highly activated in breast malignancy. On the other hand, breast cancer is one of the major causes of cancer-related morbidity and mortality worldwide, where the human epidermal growth factor receptor-positive (HER2-positive) subtype is one of the most aggressive ones with a high rate of lymph node metastasis. In this review, we summarize the association between diabetes and human cancer, listing recent evidence of metformin’s anticancer activity. A special focus is dedicated to HER2-positive breast cancer with regards to the interaction between HER2 and IGF-1R. Then, we discuss combination therapy strategies of metformin and other anti-diabetic drugs in HER2-positive breast cancer.</p><h2>Other Information</h2> <p> Published in: Biomedicine & Pharmacotherapy<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.biopha.2023.114676" target="_blank">https://dx.doi.org/10.1016/j.biopha.2023.114676</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_cbf0877cf399f4da045e9fa7a6c50aad |
| identifier_str_mv | 10.1016/j.biopha.2023.114676 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25018259 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implicationsSara S Bashraheel (17807612)Hadeel Kheraldine (14231609)Sarah Khalaf (16555642)Ala-Eddin Al Moustafa (5472368)Biomedical and clinical sciencesClinical sciencesOncology and carcinogenesisPharmacology and pharmaceutical sciencesMetforminDiabetesHER2Breast cancerHER2/IGF-1R interaction<p>Due to the strong association between diabetes and cancer incidents, several anti-diabetic drugs, including metformin, have been examined for their anticancer activity. Metformin is a biguanide antihyperglycemic agent used as a first-line drug for type II diabetes mellitus. It exhibits anticancer activity by impacting different molecular pathways, such as AMP-inducible protein kinase (AMPK)-dependent and AMPK-independent pathways. Additionally, Metformin indirectly inhibits IGF-1R signaling, which is highly activated in breast malignancy. On the other hand, breast cancer is one of the major causes of cancer-related morbidity and mortality worldwide, where the human epidermal growth factor receptor-positive (HER2-positive) subtype is one of the most aggressive ones with a high rate of lymph node metastasis. In this review, we summarize the association between diabetes and human cancer, listing recent evidence of metformin’s anticancer activity. A special focus is dedicated to HER2-positive breast cancer with regards to the interaction between HER2 and IGF-1R. Then, we discuss combination therapy strategies of metformin and other anti-diabetic drugs in HER2-positive breast cancer.</p><h2>Other Information</h2> <p> Published in: Biomedicine & Pharmacotherapy<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.biopha.2023.114676" target="_blank">https://dx.doi.org/10.1016/j.biopha.2023.114676</a></p>2023-06-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.biopha.2023.114676https://figshare.com/articles/journal_contribution/Metformin_and_HER2-positive_breast_cancer_Mechanisms_and_therapeutic_implications/25018259CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/250182592023-06-01T00:00:00Z |
| spellingShingle | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications Sara S Bashraheel (17807612) Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Metformin Diabetes HER2 Breast cancer HER2/IGF-1R interaction |
| status_str | publishedVersion |
| title | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications |
| title_full | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications |
| title_fullStr | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications |
| title_full_unstemmed | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications |
| title_short | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications |
| title_sort | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications |
| topic | Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Metformin Diabetes HER2 Breast cancer HER2/IGF-1R interaction |